Tuberculosis (TB) is a potentially serious infectious disease that primarily affects the lungs, often referred to as the 'silent killer'. Despite being preventable and curable, TB remains a major global health problem, largely due to challenges in early detection. This article provides an overview of modern diagnostic approaches for TB.
The GeneXpert MTB/RIF is a revolutionary diagnostic tool that provides results within two hours. It detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampicin (RIF), a primary drug used to treat TB. The high sensitivity and specificity of this test make it a crucial tool in TB management, especially in settings with high HIV prevalence.
Line Probe Assays (LPAs) are molecular techniques that detect both TB and drug resistance. LPAs allow for rapid detection of resistance to first and second-line drugs, crucial in the management of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
Liquid culture systems are the gold standard for TB diagnosis. They provide definitive diagnosis and drug susceptibility testing (DST), although they require several weeks to yield results. Modern systems like the MGIT 960 have improved turnaround times and increased detection rates.
CT scanning is a non-invasive imaging technique used to detect pulmonary abnormalities indicative of TB. It is particularly useful in diagnosing extrapulmonary TB and TB in children, where traditional diagnostic methods may be less effective.
Early and accurate diagnosis of TB is critical to reducing its global burden. While no single diagnostic tool is perfect, the combined use of these modern techniques can greatly improve the detection and management of TB. Continued research and development in this field are essential to unmask this silent killer.
1.
Research uncovers hidden Australian skin cancer epidemic
2.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
3.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
4.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
2.
The Importance of Maintaining Normal Calcium Levels in Your Body
3.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
4.
Metabolic Symbiosis Within the Tumor Niche: Mechanisms, Clinical Implications, and Therapeutic Opportunities
5.
A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
4.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
5.
Latest Advances in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation